|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Hospital for Special Surgery, New York |
|---|---|
| Collaborator: |
Agency for Healthcare Research and Quality (AHRQ) |
| Information provided by: | Hospital for Special Surgery, New York |
| ClinicalTrials.gov Identifier: | NCT00454467 |
Purpose
Total joint replacements are some of the most successful medical devices developed over the last fifty years. They enable millions of people to remain ambulatory and pain free, with minimal risk. In 2002, over 200,000 total hip replacements, 350,000 total knee replacements, and 25,000 total or partial shoulder replacements were performed in the United States (HCUP data). Future use will likely be even higher: it is estimated that by the year 2020, the population 65 and over in developed countries will increase by 71%. Existing studies do not provide adequate prospective data to evaluate long-term outcomes. Most health related quality of life studies in THA and TKA only report data up to twelve months post-operatively. In addition, most large studies of TKA and THA have been performed in Medicare patients. While these databases are important in providing population based data, Medicare studies do not permit any direct patient contact, and provide no information on patients under 65.
Existing studies have also investigated predictors of patient outcome at one and two years after joint arthroplasty. However, very little is known about predictors of prosthesis failure, and there are no validated clinical indicators for choosing one prosthesis model over another. Once a device is FDA approved, there is very little motivation on the part of the developer to perform complete post-marketing research, despite the importance of these data to the public health. Most existent studies are not powered to compare differences between models.
The purpose of this study is to establish a prospective cohort of HSS total knee arthroplasty.
| Condition | Intervention |
|---|---|
|
Knee Arthroplasty |
Procedure: Baseline Questionnaire Procedure: Operative Data Procedure: Intra-operative data will be collected post-operatively Procedure: In-hospital post-operative data will be collected Procedure: Satisfaction data will be extracted from Press/Ganey and on follow-up questionnaires Procedure: Cost Data Procedure: Follow-up questionnaires |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Prospective Evaluation of the Clinical and Economic Outcomes of Total Joint Replacement: The HSS Knee Arthroplasty Cohort |
| Estimated Enrollment: | 3000 |
| Study Start Date: | April 2007 |
| Estimated Study Completion Date: | April 2017 |
| Estimated Primary Completion Date: | April 2012 (Final data collection date for primary outcome measure) |
Total joint replacements are some of the most successful medical devices developed over the last fifty years. They enable millions of people to remain ambulatory and pain free, with minimal risk. In 2002, over 200,000 total hip replacements, 350,000 total knee replacements, and 25,000 total or partial shoulder replacements were performed in the United States (HCUP data). Future use will likely be even higher: it is estimated that by the year 2020, the population 65 and over in developed countries will increase by 71%. Existing studies do not provide adequate prospective data to evaluate long-term outcomes. Most health related quality of life studies in THA and TKA only report data up to twelve months post-operatively. In addition, most large studies of TKA and THA have been performed in Medicare patients. While these databases are important in providing population based data, Medicare studies do not permit any direct patient contact, and provide no information on patients under 65.
Existing studies have also investigated predictors of patient outcome at one and two years after joint arthroplasty. However, very little is known about predictors of prosthesis failure, and there are no validated clinical indicators for choosing one prosthesis model over another. Once a device is FDA approved, there is very little motivation on the part of the developer to perform complete post-marketing research, despite the importance of these data to the public health. Most existent studies are not powered to compare differences between models.
The purpose of this study is to establish a prospective cohort of HSS total knee arthroplasty.
The creation of large prospective joint arthroplasty cohorts responds directly to initiatives proposed in the NIH Consensus Development Conferences on Total Knee Replacement. This study will allow in depth analysis from the "Provider and Health Care System Perspective", (one of the important research perspectives advocated by the NIH), including surgeon, surgical technique, type of prosthesis, implantation technique and perioperative care. We will be able to evaluate all patients who receive arthroplasty surgery at HSS, as opposed to a convenience sample, and we will be able to follow patients for the life of their joint replacement. We will also be able to asses patient-level factors affecting outcomes, including medical and socio-demographic characteristics, participation in rehabilitation services, the extent of social support, and the level of patients' physical activity.
The consensus conference emphasized the importance of evaluating the use of TJA in younger patients, as these patients are underrepresented in most existing studies. For example, in one of the most rigorous existing studies of TKA, patients were followed for two years after surgery. However, three centers were needed to recruit 860 TKA patients, whose mean age was 70. By contrast, HSS alone performed over 2,000 total knee replacement surgeries in 2004, of which 41% were in patients under 65 years of age, and 28% were in patients under 60 years.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
We will be asking all patients undergoing total knee arthroplasty to participate.
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Gina Aharonoff | 646-797-8904 | aharonoffg@hss.edu |
| Contact: Nadia Camille, BS | 646-797-8594 | camillen@hss.edu |
| United States, New York | |
| Hospital for Special Surgery | Recruiting |
| New York, New York, United States, 10021 | |
| Contact: Gina Aharonoff 646-797-8904 aharonoffg@hss.edu | |
| Contact: Nadia Camille, BS 646-797-8594 camillen@hss.edu | |
| Sub-Investigator: Lisa Mandl, MD, MPH | |
| Sub-Investigator: Robert Marx, MD, MSc, FRCSC | |
| Sub-Investigator: Stephen Lyman, PhD | |
| Sub-Investigator: Alvin Mushlin, MD, ScM | |
| Sub-Investigator: Madhu Mazumdar, PhD | |
| Sub-Investigator: Steven Goldring, MD | |
| Sub-Investigator: Laura Robbins, MSW | |
| Sub-Investigator: Charles N Cornell, MD | |
| Sub-Investigator: Edward Craig, MD | |
| Sub-Investigator: Andrew Pearle, MD | |
| Sub-Investigator: Riley Williams III, MD | |
| Sub-Investigator: Hassan Ghomrawi, PhD | |
| Sub-Investigator: Stephen Incavo, MD | |
| Sub-Investigator: Geoffrey H Westrich, MD | |
| Sub-Investigator: Friedrich Boettner, MD | |
| Sub-Investigator: Mathias Bostrom, MD | |
| Sub-Investigator: Gina Aharanoff | |
| Sub-Investigator: Mark Figgie, MD | |
| Sub-Investigator: Steven Haas, MD | |
| Principal Investigator: Douglas Padgett, MD | |
| Sub-Investigator: Howard Rose, MD | |
| Sub-Investigator: Philip Wilson Jr., MD | |
| Sub-Investigator: Russell Windsor, MD | |
| Sub-Investigator: Michael Maynard, MD | |
| Sub-Investigator: Bryan Kelly, MD | |
| Sub-Investigator: Ronald Mackenzie, MD | |
| Sub-Investigator: Frank Cordasco, MD | |
| Sub-Investigator: Russell F Warren, MD | |
| Sub-Investigator: Answorth A Allen, MD | |
| Sub-Investigator: Stephen Fealy, MD | |
| Sub-Investigator: David Altchek, MD | |
| Sub-Investigator: John MacGillivray, MD | |
| Sub-Investigator: Michael Alexiades, MD | |
| Sub-Investigator: Jason Guardado | |
| Sub-Investigator: Alejandro Della Valle, MD | |
| Sub-Investigator: David Mayman, MD | |
| Sub-Investigator: Thomas Wickiewicz, MD | |
| Sub-Investigator: John Rutledge | |
| Sub-Investigator: Edwin Su, MD | |
| Sub-Investigator: Eduardo Salvati, MD | |
| Sub-Investigator: Robert Buly, MD | |
| Sub-Investigator: Kenneth Mathis, MD | |
| Sub-Investigator: Nadia Camille, BS | |
| Sub-Investigator: Justine Shum | |
| Principal Investigator: Thomas Sculco, MD | |
| Sub-Investigator: Tamara Hagoel | |
| Sub-Investigator: Daniel Fischer | |
| Sub-Investigator: Nam Giang | |
| Sub-Investigator: Kaitlyn Lillemoe | |
| Hospital for Special Surgery | Recruiting |
| New York, New York, United States, 10021 | |
| Contact: Gina Aharonoff 646-797-8904 aharonoffg@hss.edu | |
| Contact: Nadia Camille, BS 646-797-8594 camillen@hss.edu | |
| Principal Investigator: | Thomas Sculco, MD | Hospital for Special Surgery, New York |
More Information
| Responsible Party: | Dr. Thomas P. Sculco, MD, Hospital for Special Surgery |
| ClinicalTrials.gov Identifier: | NCT00454467 History of Changes |
| Other Study ID Numbers: | 26132 |
| Study First Received: | March 29, 2007 |
| Last Updated: | July 6, 2009 |
| Health Authority: | United States: Institutional Review Board |